BACKGROUND: Hemodialysis patients are at an increased risk of cardiovascular (CV) morbidity and mortality. Pulmonary hypertension (PH) has been recently reported as a new entity and unrecognized threat in maintenance hemodialysis (MHD) patients, whether PH predicts CV mortality and events in this population remains unknown. The aim of the present study was to determine the value of PH in predicting CV mortality and events in a prospective cohort of MHD patients. METHODS: We studied 278 MHD patients (98 with and 180 without PH) in Guangdong General Hospital Blood Purification Center, Guangzhou, China. All patients had been followed up for 2 years, and in survival analysis, we considered time to death or first cardiovascular event. The endpoints were all-cause mortality, CV mortality and CV events. PH was defined as systolic pulmonary artery pressure (SPAP) ≥ 35 mmHg as determined by Doppler echocardiographic evaluation. RESULTS: Of the 278 MHD patients, 53 (19.1 %) died as a result of all causes, 28 (10.1 %) died from CV events (52.8 % of causes of death), and 87 (31.3 %) had new-onset CV events. The survival curve showed that all-cause and CV mortality and new-onset CV events were higher in PH group than the non-PH group. In a multivariate Cox proportional hazard model, the adjusted HR for all-cause mortality, CV mortality and CV events was 1.85 [95 % confidence interval (CI) 1.03-3.34], 2.36 (95 % CI 1.05-5.31) and 2.27 (95 % CI 1.44-3.58), respectively. CONCLUSIONS: Our study showed that PH was an independent predictor of all-cause mortality and CV mortality and events in MHD patients. We suggest to evaluate SPAP in MHD patients in order to stratify risk of death and CV events.
BACKGROUND: Hemodialysis patients are at an increased risk of cardiovascular (CV) morbidity and mortality. Pulmonary hypertension (PH) has been recently reported as a new entity and unrecognized threat in maintenance hemodialysis (MHD) patients, whether PH predicts CV mortality and events in this population remains unknown. The aim of the present study was to determine the value of PH in predicting CV mortality and events in a prospective cohort of MHD patients. METHODS: We studied 278 MHD patients (98 with and 180 without PH) in Guangdong General Hospital Blood Purification Center, Guangzhou, China. All patients had been followed up for 2 years, and in survival analysis, we considered time to death or first cardiovascular event. The endpoints were all-cause mortality, CV mortality and CV events. PH was defined as systolic pulmonary artery pressure (SPAP) ≥ 35 mmHg as determined by Doppler echocardiographic evaluation. RESULTS: Of the 278 MHD patients, 53 (19.1 %) died as a result of all causes, 28 (10.1 %) died from CV events (52.8 % of causes of death), and 87 (31.3 %) had new-onset CV events. The survival curve showed that all-cause and CV mortality and new-onset CV events were higher in PH group than the non-PH group. In a multivariate Cox proportional hazard model, the adjusted HR for all-cause mortality, CV mortality and CV events was 1.85 [95 % confidence interval (CI) 1.03-3.34], 2.36 (95 % CI 1.05-5.31) and 2.27 (95 % CI 1.44-3.58), respectively. CONCLUSIONS: Our study showed that PH was an independent predictor of all-cause mortality and CV mortality and events in MHD patients. We suggest to evaluate SPAP in MHD patients in order to stratify risk of death and CV events.
Authors: Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza Journal: J Am Coll Cardiol Date: 2009-06-30 Impact factor: 24.094
Authors: Manoch Rattanasompattikul; Usama Feroze; Miklos Z Molnar; Ramanath Dukkipati; Csaba P Kovesdy; Allen R Nissenson; Keith C Norris; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: Int Urol Nephrol Date: 2011-11-30 Impact factor: 2.370
Authors: Carolyn S P Lam; Barry A Borlaug; Garvan C Kane; Felicity T Enders; Richard J Rodeheffer; Margaret M Redfield Journal: Circulation Date: 2009-05-11 Impact factor: 29.690
Authors: Sharanya Ramesh; Ann Zalucky; Brenda R Hemmelgarn; Derek J Roberts; Sofia B Ahmed; Stephen B Wilton; Min Jun Journal: BMC Nephrol Date: 2016-07-11 Impact factor: 2.388
Authors: Jared M O'Leary; Tufik R Assad; Meng Xu; Kelly A Birdwell; Eric Farber-Eger; Quinn S Wells; Anna R Hemnes; Evan L Brittain Journal: Pulm Circ Date: 2017-06-29 Impact factor: 3.017
Authors: Farah Anum Jameel; Abdul Mannan Junejo; Ayesha Ejaz; Qurat Ul Ain Khan; Kamran Faisal Bhopal; Ahmad Faraz; Syed Hasan Mustafa Rizvi; Fatima Ahmad; Muhammad Tahir Journal: Cureus Date: 2020-08-13